During the past decade, Tomsk NRMC conducted 62 clinical trials. In the 10-year time frame, 62 clinical trials started and 18 clinical trials were completed, i.e. on average, 29% percent of trials that started reached the finish line to date. In the past 5 years, 35 clinical trials started and 17 clinical trials were completed. i.e. 48.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tomsk NRMC" #1 sponsor was "Tomsk National Research Medical Center of the Russian Academy of Sciences" with 23 trials, followed by "Janssen Research & Development, LLC" with 11 trials sponsored, "Meshalkin Research Institute of Pathology of Circulation" with 4 trials sponsored, "Russian Academy of Medical Sciences" with 3 trials sponsored and "Actelion" with 3 trials sponsored. Other sponsors include 19 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tomsk NRMC" #1 collaborator was "Uppsala University" with 3 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "Nippon Shinyaku Co., Ltd." with 2 trials as a collaborator, "Caris Life Sciences" with 1 trials as a collaborator and "Janssen Biotech, Inc." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Tomsk NRMC" are "Schizophrenia" (4 trials), "Atrial Fibrillation" (3 trials), "Carcinoma, Non-Small-Cell Lung" (3 trials), "Ischemic Heart Disease" (3 trials) and "Acute Coronary Syndrome" (2 trials). Many other conditions were trialed in "Tomsk NRMC" in a lesser frequency.

Most popular intervention types in "Tomsk NRMC" are "Drug" (44 trials), "Procedure" (11 trials), "Other" (10 trials), "Biological" (4 trials) and "Diagnostic Test" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Amivantamab" (3 trials), "Carboplatin" (3 trials), "Pembrolizumab" (3 trials) and "Pemetrexed" (3 trials). Other intervention names were less common.

The vast majority of trials in "Tomsk NRMC" are 55 trials for "All" genders, 7 trials for "Male" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "Tomsk NRMC". undefined are not yet recruiting, 11 are recruiting, 11 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 33 completed trials in Tomsk NRMC, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Tomsk NRMC, 2 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 27 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 16 trials that are defined as “Not Applicable".

Tomsk NRMC has several departments that took part in Clinical trials: "Tyumen Cardiology Center," - 11 trials, "Tomsk scientific research institute of oncology SO RAMN, PAD; Pathological" - 2 trials